What are the factors driving the intraoperative radiation therapy market?

ZEISS is among the pioneer companies that combined surgery with radiotherapy to develop and introduce intraoperative radiation therapy to the cancer treatment field.

The global intraoperative radiation therapy market is projected to reach USD 66 million by 2025 from USD 48 million in 2020, at a CAGR of 6.4% during the forecast period. The rising incidence of cancer, technological advancements, and advantages offered by IORT are the major factors driving the growth of the global intraoperative radiation therapy market. Research and clinical trials are also being conducted to expand the applications of IORT; this will add to market growth prospects in the coming years.

To know about the assumptions considered for the study download the pdf brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=245000083

Browse in-depth TOC on "Intraoperative Radiation Therapy Market"

77 – Tables

33 – Figures

159 – Pages

Key Market Players

The key growth strategies adopted by the top players in the market are product launches and approvals, agreements, partnerships, mergers and acquisitions, and expansions. Prominent players in the intraoperative radiation therapy market include ZEISS Group (Germany), iCAD, Inc. (US), Eckert & Ziegler (Germany), Elekta AB (Sweden), GMV Innovating Solutions (Spain), Sensus Healthcare, Inc. (US), IntraOp Medical, Inc. (US), Isoray, Inc. (US), Becton, Dickinson and Company (US), Sordina IORT Technologies (Italy), Varian Medical Systems, Inc. (US), SeeDos Ltd. (UK), IsoAid LLC (US), Ariane Medical Systems Ltd. (UK), Panacea Medical Technologies Pvt. Ltd. (India), Salutaris Medical Devices (US), Brainlab AG (Germany), RaySearch Laboratories (Sweden), REMEDI Co., Ltd. (South Korea), Merit Medical Systems Inc. (US), Xstrahl Medical (UK), DOSIsoft SA (France), Huiheng Medical (China), Sun Nuclear Corporation (US), and Theragenics Corporation (US).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=245000083

ZEISS is among the pioneer companies that combined surgery with radiotherapy to develop and introduce intraoperative radiation therapy to the cancer treatment field. The flagship product of the company, INTRABEAM, is one of the most widely used IORT products across the globe. INTRABEAM is a revolutionary, intraoperative form of radiation therapy for early-stage breast cancers. It allows radiation treatment and breast-conserving surgery to be performed simultaneously. As a result, the need for several weeks of external radiation therapy following surgery can often be minimized or eliminated. The strong foothold of the company in the intraoperative radiation therapy market can be attributed to its wide geographic reach. ZEISS has a direct presence in almost 50 countries and more than 30 production sites and 25 R&D facilities. ZEISS has a sound custom services support set up, which helps it to strengthen its customer relationships and presence in the market.

iCAD, Inc. is a major player in the intraoperative radiation therapy market. The company offers a wide range of IORT products, including electronic brachytherapy products, different types of applicators, and accessories. In the last three years, the company has significantly invested in R&D activities to launch advanced products in the market. In 2019, the company invested USD 9.4 million in R&D.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=245000083

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com


N Priya

97 Blog posts

Comments